Other News To Note
Monday, April 2, 2012
Hunter Immunology Ltd., of Sydney, Australia, said it completed its merger with ASX-listed company Probiomics Ltd., of Gordon, Australia. The merged entity, which will be renamed Bioxyne and will focus on a midstage chronic obstructive pulmonary disease candidate, is due to relist on the Australian exchange on April 4.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.